Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

AtheroGenics Discontinues High Dose Of AGI-1067 In Diabetes Trial Due To Liver Toxicity

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

ANDES trial will continue to evaluate the 75 mg and 150 mg doses of AGI-1067 after termination of 300 mg dosing.

You may also be interested in...



AtheroGenics Plans Second Phase III Diabetes Study For AGI-1067

Interim analysis from ongoing ANDES trials shows Atlanta firm’s type 2 diabetes candidate significantly reduced hemoglobin A1c reduction.

AtheroGenics Plans Second Phase III Diabetes Study For AGI-1067

Interim analysis from ongoing ANDES trials shows Atlanta firm’s type 2 diabetes candidate significantly reduced hemoglobin A1c reduction.

AtheroGenics Completes Enrollment Of Phase III AGI-1067 Diabetes Study

Interim data from the randomized, double-blind, placebo-controlled trial are expected in the second quarter of 2008.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

See All
UsernamePublicRestriction

Register

PS065339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By